参考文献/References:
[1]Bolignano D,Greco M,Arcidiacono V,et al.Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients[J].J Nephrol,2021,34(2):451-458.[2]代菁,钱航,陈俊,等.同型半胱氨酸水平与维持性血透患者心血管及全因死亡的关系研究[J].湖北医药学院学报,2024,43(1):33-38.[3]胡志娟,史亚男,刘琼,等.成纤维细胞生长因子-23与慢性肾脏病患者矿物质代谢紊乱的相关性研究[J].中国现代医学杂志,2019,29(21):95-99.[4]程小莉,李开鹏,崔琼.终末期肾脏病患者骨密度与血清维生素D、尿尿酸、钙磷乘积、全段甲状旁腺激素的相关性研究[J].中国医药导报,2024,21(6):90-93.[5]彭燕,张威,郝静,等.慢性肾脏病患者成纤维细胞生长因子23与肾功能及钙磷代谢的关系[J].中华肾脏病杂志,2010,26(2):81-85.[6]Carrillo-Lopez N,Panizo S,Alonso-Montes C,et al.Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease[J].Kidney Int,2016,90(1):77-89.[7]Rodrigues RV,Giannini M,Pascon FM,et al.Effect of conditioning solutions containing ferric chloride on dentin bond strength and collagen degradation[J].Dental materials,2017,33(10):1093-1102.[8]Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder(CKD-MBD)[J].Kidney International Supplements,2017,7(1):1-59.[9]Sit D,Kadiroglu AK,Kayabasi H,et al.Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients[J].Advances in Therapy,2007,24(5):987-995.[10]陈天浩,黄正,万华,等.慢性肾脏病3～5期患者血清维生素K2与腹主动脉钙化的相关性[J].中国血液净化,2024,23(3):181-185..[11]Janiszewski T,Ko?覥t S,Ciastoń I,et al.Investigation of osteoclast cathepsin K activity in osteoclastogenesis and bone loss using a set of chemical reagents[J].Cell Chem Biol,2023,30(2):159-174.[12]Jules J,Wang S,Shi Z,et al.The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor kappaB (RANK) Cooperate to Induce Osteoclastogenesis[J].J Biol Chem,2015,290(39):23738-23750.[13]Kawai R,Sugisaki R,Miyamoto Y,et al.Cathepsin K degrades osteoprotegerin to promote osteoclastogenesis in vitro[J].In Vitro Cell Dev Biol Anim,2023,59(1):10-18. [14]Coppolino G, Marta G, Giuseppe L, et al. Altered cathepsin-k levels reflect severity of mineral bone disease and inflammation in chronic hemodialysis patients[J].Nephrology Dialysis Transplantation,2020,35(142):1417.[15]Bonnet N,Douni E,Perréard Lopreno G,et al.RANKL-Induced Increase in Cathepsin K Levels Restricts Cortical Expansion in a Periostin-Dependent Fashion: A Potential New Mechanism of Bone Fragility[J].J Bone Miner Res,2021,36(8):1636-1645.[16]黄雯,杨启,王兴纯,等.BALP、PTH联合IGF-1检测在肾性骨病早期诊断中的临床意义[J].分子诊断与治疗杂志,2022,14(7):1221-1224.[17]Armando A,Laia G,Pablo U,et al.Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis[J].Frontiers in Physiology,2023,14:1177829.[18]Ross DS,Graichen R.Increased rat femur osteocalcin mRNA concentrations following in vivo administration of thyroid hormone[J].Journal of Endocrinological Investigation,1991,14(9):763-766.[19]Bolignano D,Greco M,Arcidiacono V,et al.Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients[J].Int Urol Nephrol,2021,53(1):171-175.[20]Izumi Y,Hayashi M,Morimoto R,et al.Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients[J].Heart Vessels,2016,31(1):6-14.[21]Andrault P,Panwar P,Mackenzie NCW,et al.Elastolytic activity of cysteine cathepsins K, S, and V promotes vascular calcification[J].Scientific Reports,2019,9(1):9613-9682.[22]梁群娣,吴文军,佘子瑜.颈动脉粥样硬化斑块患者淋巴细胞功能相关抗原-1、可溶性CD40、组织蛋白酶K水平分析[J].心脑血管病防治,2021,21(1):93-94,98.[23]Fang F,Feng T,Li J,et al.Cathepsin K contributed to disturbed flow-induced atherosclerosis is dependent on integrin-actin cytoskeleton-NF-κB pathway[J].Genes Dis,2023,10(2):583-595.[24]许品品,朱丹,姚希.组织蛋白酶K升高是维持性血液透析患者心血管疾病死亡的危险因素[J].中国血液净化,2021,20(10):661-664.[25]李波,杨明,鞠东辉.声动力疗法通过下调组织蛋白酶K表达改善动脉粥样硬化[J].中国微侵袭神经外科杂志,2021,26(9):447-450.[26]郑婧,林燕珊,张健,等.老年人血清组织蛋白酶K与冠心病的相关性研究[J].实用老年医学,2019,33(10):1000-1003.[27]Vizovisek M,Vidak E,Javorsek U,et al.Cysteine cathepsins as therapeutic targets in inflammatory diseases[J].Expert Opin Ther Targets,2020,24(6):573-588.[28]Romas E,Gillespie MT,Martin TJ.Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis[J].Bone,2002,30(2):340-346.[29]周欢,欧三桃,曾光,等.维持性血液透析患者指骨骨密度与相关指标的关系[J].医学综述,2020,26(6):1228-1232.[30]Vizovisek M,Vidak E,Javorsek U,et al.Cysteine cathepsins as therapeutic targets in inflammatory diseases[J].Expert Opin Ther Targets,2020,24(6):573-588.